Literature DB >> 15731143

Nausea and vomiting due to insulin glargine in patient with type 1 diabetes mellitus.

Anthony N Dixon1, Stephen C Bain.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15731143      PMCID： PMC549657          DOI： 10.1136/bmj.330.7489.455

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  2 in total

1.  Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo.

Authors:  L Heinemann; R Linkeschova; K Rave; B Hompesch; M Sedlak; T Heise
Journal:  Diabetes Care       Date:  2000-05       Impact factor: 19.112

Review 2.  Insulin glargine.

Authors:  R K Campbell; J R White; T Levien; D Baker
Journal:  Clin Ther       Date:  2001-12       Impact factor: 3.393
  2 in total
  3 in total

1.  Insulin glargine in the management of diabetes mellitus: an evidence-based assessment of its clinical efficacy and economic value.

Authors:  Rhian Clissold; Steve Clissold
Journal:  Core Evid       Date:  2007-11-30

2.  Problems and pitfalls in modern competency-based laparoscopic training.

Authors:  M P Schijven; W A Bemelman
Journal:  Surg Endosc       Date:  2011-02-07       Impact factor: 4.584

Review 3.  Insulin glargine in the treatment of type 1 and type 2 diabetes.

Authors:  Anthony H Barnett
Journal:  Vasc Health Risk Manag       Date:  2006
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.